| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Radiotherapy, Churchill Hospital, Oxford 0X3 7LJ
* Department of Nuclear Medicine, Southampton General Hospital, Southampton S09 4XY
Amersham International, Amersham, BucksHP7 9LL
Department of Radiotherapy, Royal South Hants Hospital, Southampton S09 4PE
Department of Nuclear Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada T6G 1Z2
** Department of Radiotherapy, Freedom Fields Hospital, Plymouth, PL4 7JJ, UK
Correspondence: Address correspondence to Dr Laing, Department of Radiotherapy, Churchill Hospital, Oxford OX3 7LJ, UK.
In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 1091–1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.
Key Words: Strontium-89 • Prostate • Bone pain treatment
Received for publication January 1, 1991.
Revision received April 1, 1991.
This article has been cited by other articles:
 |
|
 |
|
  G. M. Reisfield, E. B. Silberstein, and G. R. Wilson Radiopharmaceuticals for the palliation of painful bone metastases American Journal of Hospice and Palliative Medicine, January 1, 2005; 22(1): 41 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J. Siegel, J. V. Luck Jr, and M. E. Siegel Advances in Radionuclide Therapeutics in Orthopaedics J. Am. Acad. Ortho. Surg., January 1, 2004; 12(1): 55 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sciuto, A. Festa, S. Rea, R. Pasqualoni, S. Bergomi, G. Petrilli, and C. L. Maini Effects of Low-Dose Cisplatin on 89Sr Therapy for Painful Bone Metastases from Prostate Cancer: A Randomized Clinical Trial J. Nucl. Med., January 1, 2002; 43(1): 79 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baumrucker Palliation of painful bone metastases: Strontium-89 American Journal of Hospice and Palliative Medicine, March 1, 1998; 15(2): 113 - 115. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D. AARON Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities J. Bone Joint Surg. Am., June 1, 1997; 79(6): 917 - 32. [Full Text]
|
|
|
|
 |
|
 R. G. Robinson, D. F. Preston, M. Schiefelbein, and K. G. Baxter Strontium 89 Therapy for the Palliation of Pain Due to Osseous Metastases JAMA, August 2, 1995; 274(5): 420 - 424. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Stone, C. Phillips, and W. J. Catalona Management of Cancer of the Prostate N. Engl. J. Med., February 2, 1995; 332(5): 335 - 336. [Full Text]
|
|
|
|
|
|
A. D. Aaron The Management of Cancer Metastatic to Bone JAMA, October 19, 1994; 272(15): 1206 - 1209. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |
